- Home
- FEMY vs ACXP Comparison
FEMY vs ACXP Comparison
Compare FEMY & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- ACXP
- Stock Information
- Founded
- FEMY 2004
- ACXP 2017
- Country
- FEMY United States
- ACXP United States
- Employees
- FEMY N/A
- ACXP N/A
- Industry
- FEMY Medical/Dental Instruments
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- ACXP Health Care
- Exchange
- FEMY Nasdaq
- ACXP Nasdaq
- Market Cap
- FEMY 27.2M
- ACXP 31.4M
- IPO Year
- FEMY 2021
- ACXP 2021
- Fundamental
- Price
- FEMY $1.09
- ACXP $0.83
- Analyst Decision
- FEMY Strong Buy
- ACXP Strong Buy
- Analyst Count
- FEMY 3
- ACXP 1
- Target Price
- FEMY $10.00
- ACXP $12.00
- AVG Volume (30 Days)
- FEMY 185.8K
- ACXP 248.6K
- Earning Date
- FEMY 11-12-2024
- ACXP 11-12-2024
- Dividend Yield
- FEMY N/A
- ACXP N/A
- EPS Growth
- FEMY N/A
- ACXP N/A
- EPS
- FEMY N/A
- ACXP N/A
- Revenue
- FEMY $1,260,643.00
- ACXP N/A
- Revenue This Year
- FEMY $157.75
- ACXP N/A
- Revenue Next Year
- FEMY $254.07
- ACXP N/A
- P/E Ratio
- FEMY N/A
- ACXP N/A
- Revenue Growth
- FEMY 15.33
- ACXP N/A
- 52 Week Low
- FEMY $0.73
- ACXP $0.72
- 52 Week High
- FEMY $2.40
- ACXP $5.28
- Technical
- Relative Strength Index (RSI)
- FEMY 46.31
- ACXP 33.67
- Support Level
- FEMY $1.05
- ACXP $0.72
- Resistance Level
- FEMY $1.24
- ACXP $0.91
- Average True Range (ATR)
- FEMY 0.08
- ACXP 0.11
- MACD
- FEMY -0.00
- ACXP 0.02
- Stochastic Oscillator
- FEMY 16.00
- ACXP 24.42
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.